[1]李佳丽,刘耀,文钦,等.双次自体造血干细胞移植治疗T淋巴母细胞淋巴瘤21例的临床疗效观察[J].第三军医大学学报,2016,38(12):1350-1355.
 Li Jiali,Liu Yao,Wen Qin,et al.Double autologous peripheral blood stem cells transplant for 21 patients with lymphoblastic lymphoma[J].J Third Mil Med Univ,2016,38(12):1350-1355.
点击复制

双次自体造血干细胞移植治疗T淋巴母细胞淋巴瘤21例的临床疗效观察(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第12期
页码:
1350-1355
栏目:
专题报道
出版日期:
2016-06-30

文章信息/Info

Title:
Double autologous peripheral blood stem cells transplant for 21 patients with lymphoblastic lymphoma
作者:
李佳丽刘耀文钦朱丽丹向茜茜高蕾高力张诚孔佩艳刘红陈幸华张曦
第三军医大学新桥医院全军血液病中心
Author(s):
Li Jiali Liu Yao Wen Qin Zhu Lidan Xiang Xixi Gao Lei Gao Li Zhang Cheng Kong Peiyan Liu Hong Chen Xinghua Zhang Xi

Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China

关键词:
双次自体造血干细胞移植T淋巴母细胞淋巴瘤预后
Keywords:
double hematopoietic stem cell transplantation lymphoblastic lymphoma prognosis
分类号:
R329.24; R617; R733.4
文献标志码:
A
摘要:

目的      探讨双次自体造血干细胞移植(autologous peripheral blood stem cell transplant,APSCT)治疗T淋巴母细胞淋巴瘤的临床疗效和安全性。      方法      收集2008年2月至2013年11月在我院血液病中心接受双次APSCT的T淋巴母细胞淋巴瘤患者共21例,中位年龄29岁。按照Ann Arbor标准,Ⅲ期5例,Ⅳ期16例,第1次移植前处于完全缓解(complete remission,CR)16例,部分缓解(partial remission,PR)为5例。第1次移植采用以环己亚硝脲+依托泊苷+阿糖胞苷+环磷酰胺联合方案进行预处理,以上患者在第1次移植后4~6个月进行第2次造血干细胞移植,预处理方案为伊达比星+阿糖胞苷+环磷酰胺。      结果      ①所有患者双次自体移植后造血功能均顺利重建。 ②中位随访24个月,复发3例,死亡4例(因复发死亡2例,疾病进展死亡1例,移植相关死亡1例),无病存活12例,4例疾病稳定,1例研究截止时疾病复发进展。3年预期无进展生存为68.9%,总生存率为73.6%。 ③预后相关因素中,患者的年龄、第1次移植后疾病状态是否CR影响患者的总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS),第1次移植前疾病状态是否CR影响患者的OS。      结论      双次APSCT治疗T淋巴母细胞淋巴瘤患者疗效确切, 造血重建顺利, 移植相关死亡率低,安全性好。

Abstract:

Objective      To evaluate the efficacy and safety of tandem autologous peripheral blood stem cell transplant (APSCT) for lymphoblastic lymphoma.       Methods      Clinic data of 21 patients (median age of 29) with lymphoblastic lymphoma undergoing double APSCT in our hospital from February 2008 to November 2013 were collected and analyzed in this study. By Ann Arbor staging system, they were classified into 5 cases at stage Ⅲ and 16 cases at stage Ⅳ. Before the first transplantation, 16 cases achieved complete remission (CR) and 5 cases achieved partial remission (PR). Mobilization regimen was Mit+Vds+VP16+Dex+MTX combined with G-CSF 5 μg/(kg·d). The conditioning regimens for the tandem transplantation were CCNU+VP-16+Ara-c+CTX and IDA+Ara-c+CTX respectively. The interval of the tandem transplantation was 4 to 6 months.       Results      All patients obtained prompt and sustained hematopoietic reconstitution after the tandem transplants. But 3 cases relapsed, 4 cases died (2 died of recurrence, 1 of disease progression, and 1 of transplantation related mortality), 1 case relapsed and progressed, 12 cases were still in disease-free survival, and 4 remained stable after median follow-up of 24 (2~81) months. The 3-year progression-free survival (PFS) was 68.9%, and overall survival (OS) was 72.6%. Multivariate analysis demonstrated that OS and PFS were significantly affected by the age and disease status after first transplantation. The factor influencing OS was CR status or not after first transplantation.       Conclusion      Tandem APSCT is safe and effective for lymphoblastic lymphoma, with well hematopoietic reconstitution and low transplant-related mortality.

参考文献/References:

[1]Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/ lymphoma offers curative option with subsequent stem cell transplantation[J]. Blood, 2011, 118(13): 3504-3511. DOI: 10. 1182/blood-2011-01-329441
[2]Zhang C, Chen X, Zhang X, et al. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex [J]. Transfus Apher Sci, 2008, 39(1): 21-28. DOI: 10.1016/j.transci.2008.05.011
[3]Zhang C, Zhang X, Chen X H, et al. Features and clinical outcomes in 40 patients with mixed-lineage acute leukemia in a single center[J]. Hematology, 2013, 18 (6): 309-314. DOI: 10. 1179/1607845413Y.0000000077
[4]Chen X H, Zhang C, Zhang X, et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies[J]. Biol Blood Marrow Transplant, 2009, 15(2): 266-273. DOI: 10.1016/j.bbmt.2008.11.029
[5]Sweetenham J W, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group [J]. J Clin Oncol, 2001, 19(11): 2927-2936.
[6]Levine J E, Harris R E, Loberiza F R Jr, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma[J]. Blood, 2003, 101(7): 2476-2482. DOI: 10.1182/blood-2002-05-1483
[7]肖方, 刘利, 郝淼旺, 等. 双次自体造血干细胞移植治疗T细胞非霍奇金淋巴瘤疗效观察[J]. 临床血液学杂志, 2012, 25(4): 425-429. DOI: 10.13201/j.issn.1004-2806.2012.04.007
[8]Le-Gouill S, Moreau P, Morineau N, et al. Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin’s lymphoma with poor prognosis factors: a prospective pilot study[J]. Haematologica, 2002, 87(3): 333-334.
[9]Espigado I, Rios E, Marin-Niebla A, et al. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy[J]. Transplant Proc, 2008, 40(9): 3104-3105. DOI: 10.1016/j.transproceed.2008.08.092
[10]Vranovsky A, Ladicka M, Lakota J. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin’s lymphoma [J]. Neoplasma, 2008, 55(2): 107-112.
[11]Shi Y, Zhou S, He X, et al. Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis[J]. Chin J Cancer Res, 2015, 27(1): 66-73. DOI: 10. 3978/j.issn.1000-9604.2015.02.04
[12]Thomas D A, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia[J]. Cancer, 2006, 106(7): 1569-1580. DOI: 10.1002/cncr.21776
[13]Bersvendsen H, Kolstad A, Blystad A K, et al. Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma[J]. Acta Oncol, 2014, 53(5): 680-687. DOI: 10.3109/0284186X.2013.855816
[14]Song K W, Barnett M J, Gascoyne R D, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes[J]. Ann Oncol, 2007, 18(3): 535-540. DOI: 10.1093/annonc/mdl426

更新日期/Last Update: 2016-06-07